

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A vaccine comprising a recombinant Sendai virus vector encoding a virus protein of an immunodeficiency virus, wherein the ~~virus~~ immunodeficiency viral protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them, and wherein the vaccine induces a cellular immune response specific to the ~~virus~~ immunodeficiency viral protein.
2. (previously presented) A vaccine comprising a Sendai virus vector encoding a Gag protein or a part of it, wherein the vaccine induces a cellular immune response specific to the Gag protein or the part of it.
3. (original) The vaccine of claim 1, wherein the Sendai virus vector is defective in the V gene.
4. (original) The vaccine of claim 2, wherein the Sendai virus vector is defective in the V gene.

5. (previously presented) A method for vaccination, the method comprising intranasally administering a recombinant Sendai virus vector encoding a virus protein of an immunodeficiency virus.

6. (canceled)

7. (previously presented) The method of claim 5, wherein the vaccination comprises multiple vaccine inoculations and the recombinant Sendai virus vector is inoculated at least once.

8. (canceled)

9. (previously presented) The method of claim 5, wherein the method further comprises the step of inoculating a DNA vaccine comprising a DNA encoding the genome of the immunodeficiency virus before the inoculation of the Sendai virus vector.

10. (canceled)

11. (currently amended) A method for inducing a cellular immune response specific to a virus protein of an immunodeficiency virus *in vitro*, the method comprising the steps of

(a) introducing a recombinant Sendai virus encoding the ~~virus~~ immunodeficiency viral protein into an antigen presenting cell and (b) contacting the antigen presenting cell with a T helper cell and cytotoxic T cell, thereby inducing a cellular immune response specific to the immunodeficiency viral protein.

12. (currently amended) The method of claim 11, wherein the ~~virus~~ immunodeficiency viral protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them.

13. (currently amended) The method of claim 11, wherein the ~~virus~~ immunodeficiency viral protein comprises a Gag protein or a part of it.

14. (previously presented) The method of claim 11, wherein the antigen presenting cell is an autologous herpes virus papio-immortalized B lymphoblastoid cell.

15. (previously presented) The method of claim 11, wherein said contacting step comprises co-culturing the antigen presenting cell with the T helper cell and the cytotoxic T cell in a medium.

16. (currently amended) A composition comprising a carrier and a recombinant Sendai virus vector encoding a virus protein of an immunodeficiency virus, wherein the ~~virus~~ immunodeficiency viral protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them, and wherein the vaccine induces a cellular immune response specific to the ~~virus~~ immunodeficiency viral protein.

17. (currently amended) A composition comprising a carrier and a recombinant Sendai virus vector encoding a Gag protein or a part of it, wherein the composition induces a cellular immune response specific to the Gag protein or the part of it.

18. (previously presented) The composition of claim 16, wherein the Sendai virus vector is defective in the V gene.

19. (previously presented) The composition of claim 17, wherein the Sendai virus vector is defective in the V gene.

20. (currently amended) A method for inducing a cellular immune response specific to a virus protein of an immunodeficiency virus in an animal, the method comprising the

step of intranasally administering a recombinant Sendai virus vector encoding the ~~virus~~
immunodeficiency viral protein.

21. (canceled)

22. (canceled)

23. (canceled)

24. (previously presented) The method of claim 20, wherein the method further comprises the step of inoculating a DNA vaccine comprising a DNA encoding the genome of the immunodeficiency virus before the administration of the Sendai virus vector.

25. (canceled)

26. (previously presented) The method of claim 24, wherein the genome is defective in env gene and nef gene.

27. (canceled)

28. (currently amended) The method of claim 20, wherein the ~~virus~~ immunodeficiency viral protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them.

29. (currently amended) The method of claim 20, wherein the ~~virus~~ immunodeficiency viral protein comprises the Gag protein or a part of it.

30. (previously presented) The method of claim 20, wherein the animal is a mammal.

31. (previously presented) The method of claim 30, wherein the mammal is a non-human primate.

32. (previously presented) The method of claim 30, wherein the mammal is a human.

33. (currently amended) A method for repressing propagation of an immunodeficiency virus in an animal, the method comprising intranasally administering a recombinant Sendai virus vector encoding ~~the virus~~ an immunodeficiency viral protein.

34. (canceled)

35. (canceled)

36. (canceled)

37. (previously presented) The method of claim 30, wherein the method further comprises the step of inoculating a DNA vaccine comprising a DNA encoding the genome of the immunodeficiency virus before the administration of the Sendai virus vector.

38. (canceled)

39. (previously presented) The method of claim 37, wherein the genome is defective in env gene and nef gene.

40. (canceled)

41. (currently amended) The method of claim 33, wherein the ~~virus~~ immunodeficiency viral protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them.

42. (currently amended) The method of claim 33, wherein the ~~virus~~ immunodeficiency viral protein comprises the Gag protein or a part of it.
43. (previously presented) The method of claim 33, wherein the animal is a mammal.
44. (previously presented) The method of claim 43, wherein the mammal is a non-human primate.
45. (previously presented) The method of claim 43, wherein the mammal is a human.
46. (withdrawn) The vaccine of claim 1, wherein the Sendai virus vector is defective in an envelope gene.
47. (withdrawn) The vaccine of claim 2, wherein the Sendai virus vector defective in an envelope gene.
48. (withdrawn) The vaccine of claim 46, wherein the envelope gene is F gene.
49. (withdrawn) The vaccine of claim 47, wherein the envelope gene is F gene.

50. (withdrawn) The method of claim 5, wherein the Sendai virus vector is defective in an envelope gene.
51. (withdrawn) The method of claim 50, wherein the envelope gene is F gene.
52. (withdrawn) The method of claim 11, wherein the Sendai virus vector is defective in an envelope gene.
53. (withdrawn) The method of claim 52, wherein the envelope gene is F gene.
54. (withdrawn) The composition of claim 16, wherein the Sendai virus vector is defective in an envelope gene.
55. (withdrawn) The composition of claim 17, wherein the Sendai virus vector is defective in an envelope gene.
56. (withdrawn) The composition of claim 54, wherein the envelope gene is F gene.
57. (withdrawn) The composition of claim 55, wherein the envelope gene is F gene.

58. (withdrawn) The method of claim 20, wherein the Sendai virus vector is defective in an envelope gene.

59. (withdrawn) The method of claim 58, wherein the envelope gene is F gene.

60. (withdrawn) The method of claim 33, wherein the Sendai virus vector is defective in an envelope gene.

61. (withdrawn) The method of claim 60, wherein the envelope gene is F gene.